Clinical Trials
5
min read
Why Endpoint Adjudication Remains Critical to Trial Credibility and Regulatory Confidence
Endpoint adjudication is the independent, blinded review of clinical events by an expert committee to confirm whether reported events meet protocol definitions. It reduces misclassification and site-to-site inconsistency, protecting the statistical integrity and regulatory credibility of a trial's primary and secondary endpoints.
An investigator reports a myocardial infarction. Somewhere in a database, a composite endpoint increments by one. The question nobody asks in the moment is whether that event, as documented, matches the definition written in the protocol.
Often it does. Sometimes it does not, and the direction of the error is not random. Site reporting reflects clinical judgment, local practice and, in an unblinded study, an awareness of what the patient received. Endpoint adjudication exists to convert clinical judgment into a consistent classification, applied the same way in Boston and in Bratislava.
What Endpoint Adjudication Is
Endpoint adjudication is a structured process in which reported clinical events are reviewed against protocol definitions by reviewers who are independent of the investigational sites and blinded to treatment allocation. The reviewers do not decide whether an event was managed well. They decide whether it was, by definition, the event the protocol says it is.
The distinction sounds procedural. It determines whether the primary endpoint means what the statistical analysis plan assumes it means.
What a Clinical Events Committee (CEC) does
A clinical events committee is the body that performs clinical endpoint adjudication. Its members are specialists in the relevant field, cardiologists for cardiovascular events, neurologists for stroke, and so on, and they work from source documents collected specifically for the review: discharge summaries, ECGs, imaging, laboratory results, autopsy reports.
The committee operates under a charter written before the first event is reviewed. That charter defines the endpoint definitions in operational terms, the documents required for each event type, the voting procedure, how disagreement is resolved and how the committee remains independent from the sponsor.
Why Adjudication Matters: Consistency, Bias, Credibility
How misclassification erodes statistical power
The honest version of this argument is more interesting than the usual one. A 2023 methodological review in the European Heart Journal examined adjudication across cardiovascular trials and found that for several endpoints, adjudication changes very little. For composite endpoints, all-cause mortality and stroke, there is generally no meaningful change in effect size or p-value once events are adjudicated.
Where it does matter, it matters a great deal. Agreement between site-reported and adjudicated events varies enormously by endpoint type. Cardiovascular death showed 98.1% agreement in the SHIFT trial. Myocardial infarction ranges from roughly 70% to 90% depending on context. Unstable angina falls to somewhere between 25% and 50%. Bleeding events are significantly under-reported by sites.
The starkest illustration comes from procedural trials, where a committee identified three times as many myocardial infarctions as investigators had reported: 462 against 143. An endpoint counted that inconsistently does not simply add noise. It changes the event rate the trial was powered on, and it can move an effect estimate in either direction.
So the useful conclusion is not that every endpoint needs adjudication. It is that adjudication earns its cost where event definitions are complex, where site reporting is known to drift, and where the trial cannot be blinded.
What regulators expect
Regulators do not treat adjudication as a formality, and they do not accept it as a black box either. What they look for is that the process was defined in advance, that reviewers were genuinely independent and blinded, that the event definitions used by the committee match those in the protocol and the statistical analysis plan, and that every decision is traceable back to the source documents that supported it.
The same review notes that adjudication is most likely to produce a materially different treatment effect when investigators are unblinded to treatment allocation, a finding supported by a Cochrane review of 47 trials. Open-label designs are where blinded review does the most work.
Which Endpoints Typically Require Adjudication
The pattern is consistent: the more interpretation an endpoint requires, the more adjudication changes.
Endpoint | Typical site vs committee agreement | Why |
|---|---|---|
Cardiovascular death | Very high (98.1% in SHIFT) | Objective event, though attribution of cause can still be contested |
Stroke | High | Clear clinical presentation, usually supported by imaging |
Myocardial infarction | 70% to 90%, far lower in procedural settings | Depends on biomarker thresholds and on the definition applied; periprocedural MI is systematically under-reported |
Unstable angina | 25% to 50% | Definition relies on symptom interpretation and on the decision to hospitalize |
Bleeding events | Under-reported by sites | Severity scales are applied inconsistently and minor events go undocumented |
Hospitalization for heart failure | Variable | Depends on local admission thresholds and documentation practice |
Composite endpoints such as MACE inherit the weakest component. A composite built on cardiovascular death, myocardial infarction and stroke holds up reasonably well against reporting variation. Add unstable angina or hospitalization and the picture changes, because those components carry most of the classification uncertainty.
What Good Adjudication Looks Like
The same methodological review sets out what optimal adjudication involves, and the list is a reasonable specification to hold a provider to:
A prospective approach, defined before events accumulate rather than reconstructed later
Independent voting, with a documented procedure for resolving disagreement
At least three committee members per event
Standardized endpoint definition case report forms, so every reviewer answers the same questions in the same order
Committee independence from the sponsor
A comprehensive search strategy for identifying candidate events, not only those flagged by sites
Consideration of risk-based or adaptive adjudication models, so effort concentrates where classification is genuinely uncertain
Two additional points are worth stating plainly. Blinding has to be operational, not declared: source documents must be redacted so treatment allocation cannot be inferred from a dispensation record or a laboratory value. And a clinical events committee is not a data safety monitoring board. A DSMB reviews accumulating unblinded safety and efficacy data and can recommend stopping or modifying the trial. A CEC classifies individual events against protocol definitions, stays blinded, and has no authority over the conduct of the study.
Banook has run adjudication committees since 2004 and began adjudicating major adverse cardiovascular events two years before FDA guidance addressed the subject, which is the origin of a MACE practice the group still treats as its reference discipline. Committees are staffed with cardiologists, neurologists, radiologists and pneumologists, and the operational scope covers coordination and training of committee members, charter management, collection and tracking of medical records, quality control, archiving and audit-ready project documentation. Reviews run through a secure web portal supporting real-time centralization and multilingual consensus, which matters when a committee is distributed across several countries and languages.
You can review the endpoint adjudication offering.